Cancer Drugs Likely Losers In Reformed Medicare Rules
As ever, cancer drugs were much in the news last week, with Onyx Pharmaceuticals Inc.'s stock taking a 33 percent hit after the firm disclosed a likely delay in getting its renal cancer drug approved - and the drugs are going to make headlines even more often in the months ahead. The stories may be even sadder for approved drugs.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter